Shockproof transferring device for albumin paclitaxel and use method

Abstract

The invention discloses a shockproof transferring device for albumin paclitaxel. The device comprises a box body, a sliding box is arranged in the box body, a first hemisphere sleeve and a second hemisphere sleeve are arranged in the sliding box, a first mounting groove is formed in the outer side of the position, with the maximum diameter, of the first hemisphere sleeve, a second mounting grooveis formed in the outer side of the position, with the maximum diameter, of the second hemisphere sleeve, and fastening lantern rings are arranged at the interiors of the first mounting groove and thesecond mounting groove. The device and the method have the beneficial effects that the structure is simple, the operation is easy and convenient, and the albumin paclitaxel can be prevented from generating bubbles due to jolting and shaking in the transportation process; multiple adaptive buffering structures are arranged in the device so that shaking force transmitted to the albumin paclitaxel inthe transportation process can be effectively absorbed; the temperature of the albumin paclitaxel can be reduced so as to slow down the fluidity of the albumin paclitaxel, so that it is ensured thatthe albumin paclitaxel is not prone to be inactivated, and the situation that the bubbles are generated by stirring caused by over-high fluidity is prevented; and the device can be rapidly arranged ona common transportation carrier, and is high in adaptability, simple, efficient, convenient and rapid.

Description

technical field [0001] The invention relates to the technical field of medical auxiliary equipment, in particular to a nab-paclitaxel shock-absorbing transport device and a method of use. Background technique [0002] At present, nab-paclitaxel is an expensive drug used clinically, and is suitable for the treatment of metastatic breast cancer that fails combined chemotherapy or breast cancer that recurs within 6 months after adjuvant chemotherapy. The incidence of anaphylaxis is as high as 34.7%, and even anaphylactic shock causes death. Therefore, large doses of antiallergic drugs should be given before medication. However, paclitaxel for injection (albumin-bound) does not require anti-allergic prophylaxis before administration, but there are strict requirements on the drug preparation process. After preparation, albumin-paclitaxel is in a liquid state, and air bubbles are easily generated during transportation after preparation. However, air bubbles should be avoided in t...

AI Technical Summary

Problems solved by technology

However, paclitaxel for injection (albumin-bound) does not require anti-allergic prophylaxis before administration, but there are strict requirements on the drug preparation process. After preparation, albumin-paclitaxel is in a liquid state, and air bubbles are easily generated during transportation after preparation. However, air bubbles should be avoided in the infusion, because the formation of foam will not only affect the dissolution of the drug, but also affect the infusion dose of the drug. Therefore, since the delivery of nab-paclitaxel is difficult, it is inevitable to use ordinary transportation equipment to transport nab-paclitaxel bubbles

Images